Malaria

Malaria is a parasitic infection transmitted by the bite of an infected female Anopheles mosquito, and despite being ancient, preventable, and treatable, it still kills a child roughly every minute somewhere in the world. It is the disease that most rewards clinical vigilance: a returning traveller or a febrile child in an endemic zone can look deceptively well one afternoon and be comatose by the next, because one species — Plasmodium falciparum — can multiply and sequester in the small vessels of the brain with astonishing speed.

Learning malaria well means learning a rhythm of thought that transfers to all serious infections: think of it early, confirm it fast, treat severe disease as an emergency, and never let a negative first test end the question when the story fits. This page teaches the parasite's biology, why some species kill and others merely recur, how to diagnose and stage severity, and how modern artemisinin-based therapy and prevention actually work.

Learning Objectives

• Describe the Plasmodium life cycle and link each stage to symptoms, diagnosis, and drug targets.
• Distinguish the five human malaria species and explain why P. falciparum causes severe disease and P. vivax/P. ovale cause relapses.
• Recognise the clinical features of uncomplicated versus severe malaria, including cerebral malaria.
• Diagnose malaria using thick and thin blood films and rapid diagnostic tests, and interpret their limits.
• Choose appropriate treatment (ACT, IV artesunate) and prevention (chemoprophylaxis, bed nets, vaccines).

Quick Answer

Malaria is caused by Plasmodium parasites transmitted by Anopheles mosquitoes; five species infect humans, of which P. falciparum is by far the most lethal. Classic symptoms are cyclical fever, chills, rigors, sweats, headache, and myalgia, but presentation is often non-specific, so any fever after travel to or residence in an endemic area is malaria until proven otherwise. Diagnosis rests on microscopy of thick and thin blood films (the gold standard, allowing species identification and parasite counting) or rapid antigen tests. Uncomplicated falciparum malaria is treated with an oral artemisinin-based combination therapy (ACT); severe malaria — impaired consciousness, shock, acidosis, high parasitaemia, or organ failure — is a medical emergency treated with intravenous artesunate. P. vivax and P. ovale need added primaquine or tafenoquine to clear dormant liver forms (hypnozoites) and prevent relapse. Prevention combines insecticide-treated bed nets, indoor spraying, chemoprophylaxis for travellers, and increasingly the RTS,S and R21 vaccines.

Where It Came From

Malaria has shadowed humanity for millennia. The name comes from the medieval Italian mala aria — "bad air" — because the intermittent fevers were blamed on the noxious vapours rising from marshes and swamps. That mistaken idea, miasma theory, actually contained a useful correlation: draining marshes did reduce disease, because it removed mosquito breeding grounds, even though no one yet understood why.

The scientific breakthrough came in two steps at the close of the nineteenth century. In 1880, the French army surgeon Charles Louis Alphonse Laveran, working in Algeria, peered down a microscope at the blood of a feverish soldier and saw pigmented, moving parasites inside red cells — the first proof that malaria was caused by a living organism, not bad air. Then in 1897–1898, Ronald Ross, a British officer in India, dissected mosquitoes that had fed on malaria patients and traced the parasite through the mosquito gut, proving the Anopheles mosquito was the vector. Both men won Nobel Prizes, and the marsh-draining folk wisdom finally had a mechanism.

The need that drove this work was enormous and practical: malaria crippled armies, colonial economies, and whole populations. That same pressure produced the drugs. Quinine, extracted from the bark of the South American cinchona tree, had been used since the seventeenth century — Jesuit missionaries brought it to Europe — and remained the mainstay for centuries. The Second World War spurred synthesis of chloroquine, which became the cheap global workhorse until resistance spread from the 1950s onward. The modern era began when the Chinese scientist Tu Youyou, mining ancient herbal texts during a 1960s military research programme, isolated artemisinin from sweet wormwood (Artemisia annua); it won her the 2015 Nobel Prize and is now the backbone of first-line therapy worldwide.

The Parasite and Its Life Cycle

Understanding malaria means following the parasite through two hosts. Everything clinical — the timing of fevers, the diagnostic window, the drug targets, the relapses — falls out of this cycle.

When an infected female Anopheles bites, it injects sporozoites from its salivary glands. Within minutes these travel to the liver and invade hepatocytes, where they multiply silently for one to two weeks. This is the liver (exo-erythrocytic) stage — the incubation period, when the patient feels nothing and blood tests are negative. In P. vivax and P. ovale, some parasites become dormant hypnozoites that can reactivate weeks to months later, causing the characteristic relapses of these species (a distinct concept from recrudescence, which is regrowth of blood-stage parasites after inadequate treatment).

Each infected liver cell then bursts, releasing thousands of merozoites into the blood. These invade red blood cells and begin the erythrocytic (blood) stage — the phase that causes all the symptoms and all the pathology. Inside the red cell the parasite matures from a ring form to a trophozoite to a schizont packed with new merozoites; the cell ruptures, releasing merozoites and cellular debris that trigger the abrupt paroxysm of fever, chills, and rigors. Because this cycle is roughly synchronised, fevers become periodic: about every 48 hours in P. vivax, P. ovale, and P. falciparum ("tertian"), and every 72 hours in P. malariae ("quartan"). In practice, especially with falciparum, the classic textbook periodicity is often absent and the fever is continuous or irregular — do not wait for a tidy pattern.

A few blood-stage parasites differentiate into sexual forms, gametocytes. When another mosquito bites, it ingests these; they fuse and develop in the mosquito gut, eventually producing new sporozoites in the salivary glands, completing the cycle. This is why gametocytes matter for transmission and why some drugs (like primaquine) are given specifically to kill them and block spread.

The five species at a glance. P. falciparum dominates sub-Saharan Africa and causes almost all deaths. P. vivax is the most geographically widespread (Asia, Latin America) and relapses. P. ovale (West Africa) also relapses but is milder. P. malariae causes a chronic low-grade infection that can persist for years and is linked to nephrotic syndrome. P. knowlesi, a monkey malaria of Southeast Asia, has a 24-hour cycle and can rise to dangerous parasitaemia quickly.

Why P. falciparum Kills: Sequestration and Severe Malaria

The single most important concept in malaria pathology is sequestration, and it explains why P. falciparum is a killer while the others usually are not. Red cells infected with mature falciparum parasites express a sticky protein (PfEMP1) on their surface that makes them adhere to the lining of small blood vessels — a process called cytoadherence — and clump with uninfected cells (rosetting). These sticky cells drop out of the circulating blood and lodge in the microvasculature of the brain, kidneys, gut, and placenta.

This has two devastating consequences. First, it causes microvascular obstruction and local hypoxia, damaging vital organs. Second, because mature parasites are hidden in the tissues, the peripheral blood film can underestimate the true parasite burden — a patient can be very sick with a deceptively modest film count. The other human species do not sequester significantly, which is why P. vivax and P. malariae rarely cause this kind of organ failure (though vivax can still cause severe disease and is no longer considered "benign").

Severe malaria is almost always P. falciparum (occasionally P. knowlesi or P. vivax) and is defined by any of the following in a patient with confirmed parasitaemia: impaired consciousness or coma (cerebral malaria), repeated seizures, severe anaemia, respiratory distress or acidosis (a grim prognostic sign), acute kidney injury, shock ("algid malaria"), abnormal bleeding, jaundice, hypoglycaemia, or high parasitaemia. Cerebral malaria — a diffuse encephalopathy from sequestration in cerebral vessels — carries a mortality of 15–20% even when treated, and survivors, especially children, may have lasting neurological deficits.

Worked example. A 6-year-old in rural Uganda presents with two days of fever and is now drowsy and unrousable, with a blood glucose of 2.4 mmol/L and a rapid respiratory rate. The blood film shows P. falciparum at 8% parasitaemia. This child has cerebral malaria with hypoglycaemia and acidosis — three severity criteria. The correct action is not oral medication and observation; it is immediate IV artesunate, correction of hypoglycaemia, careful (not aggressive) fluid management, and admission to the highest level of care available. Every hour of delay increases mortality.

Diagnosis: Films, RDTs, and the Traps

Because untreated falciparum malaria can kill within days, diagnosis must be fast and must be pursued aggressively whenever the exposure history fits — recent travel to or residence in an endemic area, even months earlier.

Microscopy of Giemsa-stained blood films remains the gold standard. The thick film concentrates many layers of blood and is the most sensitive for detecting parasites; the thin film preserves cell morphology and is used to identify the species and quantify parasitaemia (percentage of red cells infected), which guides severity assessment. A crucial rule: a single negative film does not exclude malaria. If suspicion remains, repeat films every 12–24 hours for a total of three sets before ruling it out, because parasites cycle in and out of detectability.

Rapid diagnostic tests (RDTs) detect parasite antigens (HRP2, specific to falciparum, or pan-species enzymes like pLDH). They are quick, need no microscope, and are invaluable in resource-limited settings. Their limits matter for exams and practice: HRP2 tests can stay positive for weeks after successful treatment (so they cannot confirm cure), and some falciparum strains (notably in parts of the Horn of Africa and South America) have hrp2 gene deletions that produce false negatives. RDTs also do not quantify parasitaemia. Molecular tests (PCR) are the most sensitive and best for low-level or mixed infections but are not usually available urgently.

A practical safety principle: in any patient with possible severe malaria, start treatment based on the first positive test — or even on strong clinical grounds while confirmation is pending — rather than waiting.

Treatment: Artemisinins and Beyond

Treatment depends on two questions: is it severe or uncomplicated, and which species?

Uncomplicated falciparum malaria is treated with an oral artemisinin-based combination therapy (ACT) — for example artemether-lumefantrine. The logic of combination is deliberate: the artemisinin component kills parasites extremely rapidly but is cleared from the body quickly, so it is paired with a longer-acting partner drug that mops up survivors and protects the artemisinin from resistance. Never use an artemisinin as monotherapy — doing so breeds resistance, which is exactly what is now emerging in the Greater Mekong region and, worryingly, in parts of East Africa.

Severe malaria is treated with intravenous artesunate, which large trials (SEAQUAMAT in adults, AQUAMAT in African children) showed reduces mortality substantially compared with the older IV quinine. A watch point: after IV artesunate, some patients develop delayed haemolytic anaemia one to three weeks later, so haemoglobin should be monitored during recovery. Once the patient can swallow and improve, therapy is completed with a full oral ACT course.

P. vivax and P. ovale require two jobs. An ACT or chloroquine (where still effective) clears the blood-stage infection and stops the acute illness — but that leaves the dormant liver hypnozoites untouched, so the patient will relapse. To achieve radical cure, add an 8-aminoquinoline: primaquine (a 14-day course) or single-dose tafenoquine. Both can cause severe haemolysis in people with G6PD deficiency, so you must test G6PD status before prescribing them — a genuinely load-bearing safety step.

Chloroquine still works for most P. vivax, P. ovale, P. malariae, and the few remaining chloroquine-sensitive falciparum regions, but widespread falciparum resistance is why ACTs replaced it as first-line.

Real-World Applications

Malaria is a daily clinical reality across the tropics and a recurring one in travel and emergency medicine everywhere else. In an endemic-country clinic, the priority is triage: identify severe cases for IV artesunate and treat uncomplicated cases with ACT, ideally after RDT confirmation to avoid over-treatment that wastes drugs and misses other causes of fever.

In a non-endemic emergency department, the key application is the febrile returning traveller. Malaria must be at the top of the differential for anyone with fever after visiting an endemic area, and it should be actively excluded with blood films, not dismissed because the patient "took some tablets" — chemoprophylaxis is imperfect and adherence is often poor. Pregnant women and young children are especially vulnerable; placental sequestration in pregnancy causes low birth weight and maternal anaemia, which is why intermittent preventive treatment in pregnancy (IPTp) is a public-health cornerstone.

At the population level, malaria control is a triumph of applied biology: insecticide-treated bed nets and indoor residual spraying attack the vector, seasonal chemoprevention protects children during transmission peaks, and the RTS,S/AS01 and R21/Matrix-M vaccines — the first parasitic-disease vaccines ever deployed at scale — now add a layer of protection for children in high-burden areas.

Common Mistakes

Mistake 1: "The blood film was negative, so it isn't malaria." Why it is wrong: parasitaemia fluctuates, and a single film can miss a real infection, especially early or with sequestering falciparum. The correction: if the clinical story fits, repeat films every 12–24 hours (up to three sets) and consider empiric treatment for severe suspicion. One negative test never closes the case.

Mistake 2: Waiting for the classic 48-hour fever pattern before considering malaria. Why it is wrong: the tidy tertian/quartan periodicity is often absent, particularly in falciparum and early infection, where fever is commonly continuous or irregular. The correction: rely on exposure history plus any fever, not on fever timing.

Mistake 3: Giving primaquine or tafenoquine without checking G6PD status. Why it is wrong: these drugs cause acute, potentially life-threatening haemolysis in G6PD-deficient patients, who are common in malaria-endemic populations. The correction: always test G6PD before prescribing an 8-aminoquinoline for radical cure.

Mistake 4 (bonus): Treating uncomplicated malaria with artemisinin monotherapy. Why it is wrong: it accelerates resistance and risks recrudescence. The correction: always use a full artemisinin-based combination therapy course.

Comparison and Connections

The most exam-relevant comparison is between species, because it drives both prognosis and treatment.

Feature	P. falciparum	P. vivax / P. ovale	P. malariae	P. knowlesi
Main region	Sub-Saharan Africa	Asia, Latin America (vivax); West Africa (ovale)	Focal, worldwide	Southeast Asia
Severity	High — causes most deaths	Usually milder (vivax can be severe)	Chronic, low-grade	Can be severe, rises fast
Sequestration	Yes (cerebral, organ failure)	No	No	Limited
Dormant liver forms (relapse)	No	Yes (hypnozoites)	No	No
Fever cycle	48 h, often irregular	48 h	72 h	24 h
Radical cure needs primaquine	No	Yes	No	No

Two other distinctions students confuse: relapse versus recrudescence. Relapse is reactivation of dormant liver hypnozoites (vivax/ovale only) weeks to months later. Recrudescence is regrowth of surviving blood-stage parasites after inadequate treatment or resistance, and can happen with any species. And chemoprophylaxis versus radical cure: prophylaxis suppresses blood-stage infection to prevent illness during exposure; radical cure eradicates liver hypnozoites to prevent later relapse.

Malaria connects tightly to red-cell genetics — sickle cell trait, thalassaemia, and G6PD deficiency all persist in populations because they confer partial protection against falciparum, a classic example of balancing selection. For the immunology of chronic parasite infection, see Immunology; for the drug classes and resistance mechanics, see Pharmacology and Microbiology.

Practice Questions

Recall

Q: Which Plasmodium species cause relapsing malaria, and what parasite form is responsible? A: P. vivax and P. ovale, due to dormant liver-stage hypnozoites that reactivate weeks to months after the initial infection.

Understanding

Q: Why is P. falciparum so much more dangerous than the other human species? A: Because falciparum-infected red cells sequester — they cytoadhere to small-vessel walls via PfEMP1 — obstructing the microvasculature of the brain, kidneys, and placenta and causing organ failure. This also means peripheral films can underestimate the true burden. Other species do not sequester significantly.

Application

Q: A traveller returns from Nigeria with fever; the first thick film is negative. What do you do? A: Do not rule out malaria. Repeat blood films every 12–24 hours (up to three sets), consider an RDT, and maintain a high index of suspicion. If the patient shows any severity features, treat empirically with IV artesunate while confirming.

Analysis

Q: A patient with P. vivax is treated with chloroquine, recovers, then relapses two months later. Before giving primaquine for radical cure, what must you check and why? A: Check G6PD status. Primaquine (and tafenoquine) cause severe oxidative haemolysis in G6PD-deficient patients. The relapse occurred because chloroquine cleared blood-stage parasites but not the liver hypnozoites, which an 8-aminoquinoline is needed to eradicate.

FAQ

Is malaria contagious from person to person? No, not through ordinary contact. It spreads via the Anopheles mosquito. Rare exceptions are transmission through blood transfusion, shared needles, organ transplant, or from mother to baby across the placenta (congenital malaria).

How soon after a mosquito bite do symptoms appear? Usually 7 to 30 days. Falciparum typically presents within a month; vivax and ovale can appear months later because of dormant liver forms, and partial prophylaxis can delay onset further. This is why exposure history months back still matters.

If I take antimalarial tablets while travelling, am I fully protected? No prophylaxis is 100% effective, and adherence is often imperfect. Chemoprophylaxis greatly reduces risk but does not eliminate it, so any fever during or after travel still needs evaluation for malaria.

Why do I need a combination drug instead of just the artemisinin? Artemisinin kills parasites fast but leaves the body quickly. Pairing it with a longer-acting partner drug clears any survivors and protects the artemisinin from resistance. Using artemisinin alone breeds resistant parasites, which is now a real and spreading threat.

Can you catch malaria more than once? Yes. Immunity to malaria is partial and short-lived; people in endemic areas develop some protection against severe disease over years of repeated infection, but it wanes if they leave, which is why returning expatriates and their children can become severely ill.

Does malaria have a cure, or does it stay in you for life? Blood-stage malaria is fully curable with proper treatment. For vivax and ovale, you also need primaquine or tafenoquine to clear dormant liver forms; without that step the infection can relapse. P. malariae can persist at low levels for years if inadequately treated.

Quick Revision

• Caused by Plasmodium (5 species); P. falciparum is the big killer; spread by female Anopheles mosquitoes.
• Life cycle: sporozoites → liver stage (incubation; hypnozoites in vivax/ovale) → blood stage (all symptoms) → gametocytes (transmission).
• P. falciparum sequesters → cerebral malaria and organ failure; films can underestimate burden.
• Any fever after endemic-area exposure = malaria until excluded. One negative film does NOT rule it out — repeat up to 3 sets.
• Diagnosis: thick film (detect), thin film (species + parasitaemia), RDTs (fast, but HRP2 can be falsely negative or stay positive after cure).
• Uncomplicated falciparum → oral ACT; severe malaria → IV artesunate (watch for delayed haemolysis).
• Vivax/ovale → add primaquine or tafenoquine for radical cure, but check G6PD first.
• Prevention: bed nets, indoor spraying, chemoprophylaxis, IPTp in pregnancy, RTS,S/R21 vaccines.

Related Topics

Prerequisites

• Microbiology — parasite biology and vector-borne disease basics.
• The Medicine of Infections and How to Treat Them — how pathogens cause disease and the logic of therapy.

Related Topics

• Fever of Unknown Origin — approach to the persistently febrile patient.
• Antimicrobial Resistance and Antibiotic Stewardship — the same resistance logic that threatens artemisinins.
• Pharmacology — antimalarial drug classes and mechanisms.

Next Topics

• Sepsis and Septic Shock — recognising and resuscitating the critically ill febrile patient.
• Dengue Fever — another key mosquito-borne tropical fever to distinguish from malaria.